Dr. Glen MacDonald is Viventia’s most senior research executive and is responsible for the Company’s overall research and operational activities at Viventia's Winnipeg facility. In regard to research, Dr. MacDonald oversees the management and implementation of Viventia’s core technology platforms: Hybridomics™, ImmunoMine™, UnLock™ and Armed Antibodies™, as well as Viventia’s Process Sciences Department. In addition, Dr. MacDonald is responsible for the operational areas involved in the cGMP manufacture of Viventia’s clinical products. Dr. MacDonald joined Viventia Biotechnologies in July, 1997 and has held positions of increasing responsibility within the company becoming the Vice President, Research in 2004. Prior to joining Viventia Biotechnologies, Dr. MacDonald was with The University of Manitoba Cancer Treatment Research Foundation, The University of North Carolina, Chapel Hill, and the Ontario Cancer Institute, Princess Margaret Hospital.
Dr. MacDonald holds a Ph.D. from The University of Manitoba and has published in the areas of monoclonal antibodies, graft-versus-host disease, lupus and apoptosis.
|
